<p>Ovarian cancer is a gynecological malignant tumor with the highest mortality rate, 70% of patients are diagnosed at an advanced stage, 70% of ovarian cancer patients relapse within 2–3&#xa0;years, and the 5-year survival rate is always hovering around 40%, which is lower than the overall goal of "Healthy China 2030". Although the treatment of ovarian cancer has entered the era of multidisciplinary comprehensive treatment, the high recurrence of ovarian cancer, refractory ascites and malignant intestinal obstruction are still the bottleneck of treatment. As one of the important means in the comprehensive treatment of ovarian cancer, traditional Chinese medicine (TCM) has great significance in reducing the postoperative recurrence rate, improving malignant intestinal obstruction, controlling refractory ascites, reducing adverse drug reactions, and prolonging the survival time of patients. However, different hospitals and doctors lack unified standards and norms in syndrome differentiation criteria, selection of prescription and medication, use method and dosage of prescription, which affects the promotion and application of effective programs. At present, there is no unified TCM diagnosis and treatment guidelines for ovarian cancer in China. Therefore, there is an urgent need for TCM diagnosis and treatment guidelines for ovarian cancer in line with China's national conditions. In 2018, the Cancer Society of Chinese Society of Traditional Chinese Medicine was entrusted by the National Administration of Traditional Chinese Medicine, and led by the Cancer Traditional Medicine Committee of Chinese anti-Cancer Association to jointly formulate "the TCM Diagnosis and Treatment Plan for Ovarian Cancer". aiming to further improve the understanding of TCM diagnosis and treatment of ovarian cancer among clinical first-line physicians and improve the level of integrated diagnosis and treatment of Chinese and Western ovarian cancer in China.</p>